Advertisement

Breast Cancer Research and Treatment

, Volume 158, Issue 3, pp 421–432 | Cite as

Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status

  • Martinus A. BeekEmail author
  • Paul D. Gobardhan
  • Ernst J. P. Schoenmaeckers
  • Elisabeth G. Klompenhouwer
  • Harm J. T. Rutten
  • Adri C. Voogd
  • Ernest J. T. Luiten
Review

Abstract

Axillary reverse mapping (ARM) is a technique by which the lymphatic drainage of the upper extremity that traverses the axillary region can be differentiated from the lymphatic drainage of the breast during axillary lymph node dissection (ALND). Adding this procedure to ALND may reduce upper extremity lymphedema by preserving upper extremity drainage. This review of the current literature on the ARM procedure discusses the feasibility, safety and relevance of this technique. A PubMed literature search was performed until 12 August 2015. A total of 31 studies were included in this review. The studies indicated that the ARM procedure adequately identifies the upper extremity lymph nodes and lymphatics in the axillary basin using blue dye or fluorescence. Preservation of ARM lymph nodes and corresponding lymphatics was proven to be oncologically safe in clinically node-negative breast cancer patients with metastatic lymph node involvement in the sentinel lymph node (SLN) who are advised to undergo a completion ALND. The ARM procedure is technically feasible with a high visualisation rate using blue dye or fluorescence. ALND combined with ARM can be regarded as a promising surgical refinement in order to reduce the incidence of upper extremity lymphedema in selected groups of patients.

Keywords

Axillary reverse mapping Breast cancer Lymphedema 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Tausch C, Baege A, Dietrich D, Vergin I, Heuer H, Heusler RH, Rageth C (2013) Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients? Eur J Surg Oncol 39(8):880–886. doi: 10.1016/j.ejso.2013.05.009 CrossRefPubMedGoogle Scholar
  2. 2.
    Noguchi M, Morioka E, Ohno Y, Noguchi M, Nakano Y, Kosaka T (2013) The changing role of axillary lymph node dissection for breast cancer. Breast Cancer 20(1):41–46. doi: 10.1007/s12282-012-0416-4 CrossRefPubMedGoogle Scholar
  3. 3.
    Blanchard DK, Donohue JH, Reynolds C, Grant CS (2003) Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 138(5):482–487. doi: 10.1001/archsurg.138.5.482 (discussion 487–488) CrossRefPubMedGoogle Scholar
  4. 4.
    Haid A, Koberle-Wuhrer R, Knauer M, Burtscher J, Fritzsche H, Peschina W, Jasarevic Z, Ammann M, Hergan K, Sturn H, Zimmermann G (2002) Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 73(1):31–36CrossRefPubMedGoogle Scholar
  5. 5.
    Leidenius M, Leivonen M, Vironen J, von Smitten K (2005) The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 92(1):23–31. doi: 10.1002/jso.20373 CrossRefPubMedGoogle Scholar
  6. 6.
    Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9):599–609. doi: 10.1093/jnci/djj158 CrossRefPubMedGoogle Scholar
  7. 7.
    Ronka R, von Smitten K, Tasmuth T, Leidenius M (2005) One-year morbidity after sentinel node biopsy and breast surgery. Breast 14(1):28–36. doi: 10.1016/j.breast.2004.09.010 CrossRefPubMedGoogle Scholar
  8. 8.
    Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME, Voogd AC (2003) Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29(4):341–350CrossRefPubMedGoogle Scholar
  9. 9.
    Schrenk P, Rieger R, Shamiyeh A, Wayand W (2000) Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 88(3):608–614CrossRefPubMedGoogle Scholar
  10. 10.
    Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM (2002) Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 9(8):745–753CrossRefPubMedGoogle Scholar
  11. 11.
    Noguchi M, Miwa K, Michigishi T, Yokoyama K, Nishijima H, Takanaka T, Kawashima H, Nakamura S, Kanno H, Nonomura A (1997) The role of axillary lymph node dissection in breast cancer management. Breast Cancer 4(3):143–153CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook KC, Klimberg VS (2007) Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 14(6):1890–1895. doi: 10.1245/s10434-007-9412-x CrossRefPubMedGoogle Scholar
  13. 13.
    Nos C, Lesieur B, Clough KB, Lecuru F (2007) Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol 14(9):2490–2496. doi: 10.1245/s10434-007-9450-4 CrossRefPubMedGoogle Scholar
  14. 14.
    Pavlista D, Eliska O (2012) Analysis of direct oil contrast lymphography of upper limb lymphatics traversing the axilla—a lesson from the past—contribution to the concept of axillary reverse mapping. Eur J Surg Oncol 38(5):390–394. doi: 10.1016/j.ejso.2012.01.010 CrossRefPubMedGoogle Scholar
  15. 15.
    Hama Y, Koyama Y, Urano Y, Choyke PL, Kobayashi H (2007) Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat 103(1):23–28. doi: 10.1007/s10549-006-9347-0 CrossRefPubMedGoogle Scholar
  16. 16.
    Deng H, Chen L, Jia W, Chen K, Zeng Y, Rao N, Li S, Jin L, Su F (2011) Safety study of axillary reverse mapping in the surgical treatment for breast cancer patients. J Cancer Res Clin Oncol 137(12):1869–1874. doi: 10.1007/s00432-011-1064-3 CrossRefPubMedGoogle Scholar
  17. 17.
    Han JW, Seo YJ, Choi JE, Kang SH, Bae YK, Lee SJ (2012) The efficacy of arm node preserving surgery using axillary reverse mapping for preventing lymphedema in patients with breast cancer. J Breast Cancer 15(1):91–97. doi: 10.4048/jbc.2012.15.1.91 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pasko JL, Garreau J, Carl A, Ansteth M, Glissmeyer M, Johnson N (2015) Axillary reverse lymphatic mapping reduces patient perceived incidence of lymphedema after axillary dissection in breast cancer. Am J Surg. doi: 10.1016/j.amjsurg.2015.01.011 PubMedGoogle Scholar
  19. 19.
    Casabona F, Bogliolo S, Valenzano Menada M, Sala P, Villa G, Ferrero S (2009) Feasibility of axillary reverse mapping during sentinel lymph node biopsy in breast cancer patients. Ann Surg Oncol 16(9):2459–2463. doi: 10.1245/s10434-009-0554-x CrossRefPubMedGoogle Scholar
  20. 20.
    Ochoa D, Korourian S, Boneti C, Adkins L, Badgwell B, Klimberg VS (2014) Axillary reverse mapping: five-year experience. Surgery 156(5):1261–1268. doi: 10.1016/j.surg.2014.05.011 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kuusk U, Seyednejad N, McKevitt EC, Dingee CK, Wiseman SM (2014) Axillary reverse mapping in breast cancer: a Canadian experience. J Surg Oncol 110(7):791–795. doi: 10.1002/jso.23720 CrossRefPubMedGoogle Scholar
  22. 22.
    Clough KB, Nasr R, Nos C, Vieira M, Inguenault C, Poulet B (2010) New anatomical classification of the axilla with implications for sentinel node biopsy. Br J Surg 97(11):1659–1665. doi: 10.1002/bjs.7217 CrossRefPubMedGoogle Scholar
  23. 23.
    Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F (2010) A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 116(11):2543–2548. doi: 10.1002/cncr.25096 PubMedPubMedCentralGoogle Scholar
  24. 24.
    Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, Lecuru F (2008) Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol 15(9):2550–2555. doi: 10.1245/s10434-008-0030-z CrossRefPubMedGoogle Scholar
  25. 25.
    Connor C, McGinness M, Mammen J, Ranallo L, Lafaver S, Klemp J, Fan F, Mahnken J (2013) Axillary reverse mapping: a prospective study in women with clinically node negative and node positive breast cancer. Ann Surg Oncol 20(10):3303–3307. doi: 10.1245/s10434-013-3113-4 CrossRefPubMedGoogle Scholar
  26. 26.
    Khandelwal R, Poovamma CU, Shilpy C, Prema M, Anthony P (2014) Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients? Breast Dis 34(4):151–155. doi: 10.3233/BD-140371 CrossRefPubMedGoogle Scholar
  27. 27.
    Ponzone R, Cont NT, Maggiorotto F, Cassina E, Mininanni P, Biglia N, Sismondi P (2009) Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. J Clin Oncol 27(33):5547–5551. doi: 10.1200/JCO.2009.22.1846 CrossRefPubMedGoogle Scholar
  28. 28.
    Schunemann E Jr, Doria MT, Silvestre JB, Gasperin P Jr, Cavalcanti TC, Budel VM (2014) Prospective study evaluating oncological safety of axillary reverse mapping. Ann Surg Oncol 21(7):2197–2202. doi: 10.1245/s10434-014-3626-5 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rubio IT, Cebrecos I, Peg V, Esgueva A, Mendoza C, Cortadellas T, Cordoba O, Espinosa-Bravo M, Xercavins J (2012) Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer. J Surg Oncol 106(1):89–93. doi: 10.1002/jso.23048 CrossRefPubMedGoogle Scholar
  30. 30.
    Boneti C, Badgwell B, Robertson Y, Korourian S, Adkins L, Klimberg V (2012) Axillary reverse mapping (ARM): initial results of phase II trial in preventing lymphedema after lymphadenectomy. Minerva Ginecol 64(5):421–430PubMedGoogle Scholar
  31. 31.
    Boneti C, Korourian S, Bland K, Cox K, Adkins LL, HenryTillman RS, Klimberg VS (2008) Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg 206(5):1038–1042. doi: 10.1016/j.jamcollsurg.2007.12.022 (discussion 1042–1034) CrossRefPubMedGoogle Scholar
  32. 32.
    Boneti C, Korourian S, Diaz Z, Santiago C, Mumford S, Adkins L, Klimberg VS (2009) Scientific Impact Award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg 198(4):482–487. doi: 10.1016/j.amjsurg.2009.06.008 CrossRefPubMedGoogle Scholar
  33. 33.
    Gobardhan PD, Wijsman JH, van Dalen T, Klompenhouwer EG, van der Schelling GP, Los J, Voogd AC, Luiten EJ (2012) ARM: axillary reverse mapping—the need for selection of patients. Eur J Surg Oncol 38(8):657–661. doi: 10.1016/j.ejso.2012.04.012 CrossRefPubMedGoogle Scholar
  34. 34.
    Klimberg VS (2008) A new concept toward the prevention of lymphedema: axillary reverse mapping. J Surg Oncol 97(7):563–564. doi: 10.1002/jso.20905 CrossRefPubMedGoogle Scholar
  35. 35.
    Yue T, Zhuang D, Zhou P, Zheng L, Fan Z, Zhu J, Hou L, Yu F, Dong X, Xiao L, He Q (2015) A prospective study to assess the feasibility of axillary reverse mapping and evaluate its effect on preventing lymphedema in breast cancer patients. Clin Breast Cancer. doi: 10.1016/j.clbc.2015.01.010 Google Scholar
  36. 36.
    Gobardhan PD, Klompenhouwer EG, Beek MA, Voogd AC, Luiten EJ (2013) Axillary reverse mapping. preserving nodes during an axillary lymph node dissection. Ned Tijdschr Geneeskd 157(22):A5646PubMedGoogle Scholar
  37. 37.
    Noguchi M, Yokoi M, Nakano Y (2010) Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer. J Surg Oncol 101(3):217–221. doi: 10.1002/jso.21473 PubMedGoogle Scholar
  38. 38.
    Noguchi M, Noguchi M, Nakano Y, Ohno Y, Kosaka T (2012) Axillary reverse mapping using a fluorescence imaging system in breast cancer. J Surg Oncol 105(3):229–234. doi: 10.1002/jso.22094 CrossRefPubMedGoogle Scholar
  39. 39.
    Ikeda K, Ogawa Y, Kajino C, Deguchi S, Kurihara S, Tashima T, Goto W, Nishiguchi Y, Tokunaga S, Fukushima H, Inoue T (2014) The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients. Eur J Surg Oncol 40(7):818–823. doi: 10.1016/j.ejso.2014.03.023 CrossRefPubMedGoogle Scholar
  40. 40.
    Ikeda K, Ogawa Y, Komatsu H, Mori Y, Ishikawa A, Nakajima T, Oohira G, Tokunaga S, Fukushima H, Inoue T (2012) Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients. World J Surg Oncol 10:233. doi: 10.1186/1477-7819-10-233 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sakurai T, Endo M, Shimizu K, Yoshimizu N, Nakajima K, Nosaka K, Dai Y, Iwao A, Jinnai Y (2014) Axillary reverse mapping using fluorescence imaging is useful for identifying the risk group of postoperative lymphedema in breast cancer patients undergoing sentinel node biopsies. J Surg Oncol 109(6):612–615. doi: 10.1002/jso.23528 CrossRefPubMedGoogle Scholar
  42. 42.
    Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK (2012) The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 19(10):3177–3184. doi: 10.1245/s10434-012-2484-2 CrossRefPubMedGoogle Scholar
  43. 43.
    Beek MA, Gobardhan PD, Klompenhouwer EG, Rutten HJ, Voogd AC, Luiten EJ (2015) Axillary reverse mapping (ARM) in clinically node positive breast cancer patients. Eur J Surg Oncol 41(1):59–63. doi: 10.1016/j.ejso.2014.09.012 CrossRefPubMedGoogle Scholar
  44. 44.
    Beek MA, Tetteroo E, Luiten EJ, Gobardhan PD, Rutten HJ, Heijns JB, Voogd AC, Klompenhouwer EG (2016) Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy. Eur J Surg Oncol. doi: 10.1016/j.ejso.2016.02.005 Google Scholar
  45. 45.
    Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN (2003) Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 55(5):1209–1215CrossRefPubMedGoogle Scholar
  46. 46.
    Britton TB, Solanki CK, Pinder SE, Mortimer PS, Peters AM, Purushotham AD (2009) Lymphatic drainage pathways of the breast and the upper limb. Nucl Med Commun 30(6):427–430. doi: 10.1097/MNM.0b013e328315a6c6 CrossRefPubMedGoogle Scholar
  47. 47.
    Gennaro M, Maccauro M, Sigari C, Casalini P, Bedodi L, Conti AR, Caraceni A, Bombardieri E (2013) Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema. Eur J Surg Oncol 39(12):1341–1345. doi: 10.1016/j.ejso.2013.09.022 CrossRefPubMedGoogle Scholar
  48. 48.
    Klompenhouwer EG, Gobardhan PD, Beek MA, Voogd AC, Luiten EJ (2013) The clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial. Trials 14:111. doi: 10.1186/1745-6215-14-111 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Martinus A. Beek
    • 1
    Email author
  • Paul D. Gobardhan
    • 1
  • Ernst J. P. Schoenmaeckers
    • 1
  • Elisabeth G. Klompenhouwer
    • 2
  • Harm J. T. Rutten
    • 3
    • 4
  • Adri C. Voogd
    • 4
    • 5
  • Ernest J. T. Luiten
    • 1
  1. 1.Department of SurgeryAmphia HospitalBredaThe Netherlands
  2. 2.Department of RadiologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of SurgeryCatharina HospitalEindhovenThe Netherlands
  4. 4.GROW: School of Oncology and Developmental BiologyMaastricht UniversityMaastrichtThe Netherlands
  5. 5.Department of ResearchNetherlands Comprehensive Cancer OrganisationUtrechtThe Netherlands

Personalised recommendations